| Literature DB >> 28669328 |
Niki Katsiki1, Pablo Perez-Martinez2,3, Panagiotis Anagnostis1,4, Dimitri P Mikhailidis5, Asterios Karagiannis1.
Abstract
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD. In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Non-alcoholic fatty liver disease; anti-obesity drugs; antidiabeticzzm321990drugs; antihypertensive drugs.; cardiovascular risk; hypolipidaemic drugs; metabolic syndrome; risk factors
Mesh:
Substances:
Year: 2018 PMID: 28669328 DOI: 10.2174/1570161115666170621075619
Source DB: PubMed Journal: Curr Vasc Pharmacol ISSN: 1570-1611 Impact factor: 2.719